Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 0.53 |
| ▸ | RHEB | Q15382 | 4/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603094 | 0.93 | GRIN1 (0.51) | GRIN1SMYD3RHEBNUDT1 | |
| SCHEMBL3611191 | 0.93 | GRIN1 (0.51) | GRIN1SMYD3RHEBNUDT1 | |
| SCHEMBL3603096 | 0.93 | GRIN1 (0.51) | GRIN1SMYD3RHEBNUDT1 | |
| SCHEMBL17206304 | 0.88 | GRIN1 (0.55) | GRIN1SMYD3RHEBNUDT1MLLT1 | |
| SCHEMBL15506883 | 0.86 | GRIN1 (0.50) | GRIN1SMYD3RHEBNUDT1MLLT1 | |
| SCHEMBL15506791 | 0.86 | GRIN1 (0.52) | GRIN1SMYD3RHEBNUDT1MLLT1 | |
| SCHEMBL15520457 | 0.86 | GRIN1 (0.52) | GRIN1SMYD3RHEBNUDT1MLLT1 | |
| SCHEMBL15506783 | 0.86 | GRIN1 (0.52) | GRIN1SMYD3RHEBNUDT1MLLT1 | |
| SCHEMBL3594650 | 0.86 | SMYD3 (0.46) | GRIN1SMYD3RHEBNUDT1 | |
| Trifluoroacetic Acid SCHEMBL3612509 | 0.85 | GRIN1 (0.47) | GRIN1SMYD3RHEBNUDT1MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | GRIN1 650/4885SMYD3 811/4885RHEB 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.